Table 1

Baseline characteristics of the European and Japanese trial populations (full analysis sets)
European population [23] Japanese population [24]
DNG (n= 120) GnRH analogue (n= 128) DNG (n= 128) GnRH analogue (n= 125)
Age (years, mean ± SD) 30.6 ± 6.2 31.0 ± 5.8 33.5 ± 6.9 33.8 ± 6.2
Weight (kg, mean ± SD) 62.5 ± 10.8 62.7 ± 9.6 52.1 ± 7.1 53.3 ± 8.2
Lumbar BMD (g/cm2, mean ± SD) 1.06 ± 0.1 (n = 26) 1.07 ± 0.1 (n = 31) 1.04 ± 0.1 (n = 41) 1.03 ± 0.1 (n = 46)

DNG, dienogest (2 mg/day); GnRH, gonadotropin-releasing hormone analogue; BMD, bone mineral density. GnRH analogues: European trial, leuprolide acetate 3.75 mg intramuscular injection, four-weekly; Japanese trial, buserelin acetate 3 × 300 μg/day, intranasally.

Gerlinger et al.

Gerlinger et al. BMC Women's Health 2012 12:9   doi:10.1186/1472-6874-12-9

Open Data